2025 Europe Anti-Retroviral Drugs Revenue Opportunities Report
Description
The 2025 Europe Anti-Retroviral Drugs Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Retroviral Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antiretroviral Drugs (ARV) market in Europe are Gilead Sciences, ViiV Healthcare, Janssen Pharmaceuticals, and Merck & Co. Gilead leads with a significant portfolio of HIV therapeutics, including the highly successful Biktarvy, which generated about $12 billion globally in 2023. The company is also advancing long-acting therapies such as lenacapavir to improve adherence and treatment outcomes. ViiV Healthcare, a GlaxoSmithKline joint venture, focuses on innovative integrase strand transfer inhibitors like cabotegravir and partners with other manufacturers to enhance injectable treatments. Janssen Pharmaceuticals (part of Johnson & Johnson) and Merck are also key players investing in integrase inhibitors and combination regimens to address treatment resistance and comorbidities among people living with HIV.
These companies are pivotal in Europe’s HIV therapeutics market, valued at over USD 6 billion and growing due to the rising prevalence of HIV/AIDS, especially in Eastern Europe and major German cities. They collaborate on pipeline innovations and access programs to expand treatment reach and optimize long-acting and single-tablet regimens, which are reshaping HIV care by reducing pill burden and enhancing viral suppression. Their combined efforts, including strategic research, clinical trials, and partnerships, drive forward therapeutic options aiming at both management and eventual cure prospects in the European HIV/AIDS landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Retroviral Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Antiretroviral Drugs (ARV) market in Europe are Gilead Sciences, ViiV Healthcare, Janssen Pharmaceuticals, and Merck & Co. Gilead leads with a significant portfolio of HIV therapeutics, including the highly successful Biktarvy, which generated about $12 billion globally in 2023. The company is also advancing long-acting therapies such as lenacapavir to improve adherence and treatment outcomes. ViiV Healthcare, a GlaxoSmithKline joint venture, focuses on innovative integrase strand transfer inhibitors like cabotegravir and partners with other manufacturers to enhance injectable treatments. Janssen Pharmaceuticals (part of Johnson & Johnson) and Merck are also key players investing in integrase inhibitors and combination regimens to address treatment resistance and comorbidities among people living with HIV.
These companies are pivotal in Europe’s HIV therapeutics market, valued at over USD 6 billion and growing due to the rising prevalence of HIV/AIDS, especially in Eastern Europe and major German cities. They collaborate on pipeline innovations and access programs to expand treatment reach and optimize long-acting and single-tablet regimens, which are reshaping HIV care by reducing pill burden and enhancing viral suppression. Their combined efforts, including strategic research, clinical trials, and partnerships, drive forward therapeutic options aiming at both management and eventual cure prospects in the European HIV/AIDS landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
